Benefits
Estrogen Metabolism Modulation
Bradlow 1999 trial showed I3C 400 mg/day shifted estrogen metabolism toward favorable 2-hydroxyestrone:16-alpha-hydroxyestrone ratio. Foundational mechanism — same effect as DIM.
Recurrent Respiratory Papillomatosis (RRP) Adjunct
Rosen 1998 trial showed I3C reduced papilloma recurrence in patients with juvenile/adult RRP. Mechanism: anti-HPV effects, immune modulation. Modest clinical evidence; adjunct only.
Cervical Dysplasia Adjunct
Bell 2000 trial showed I3C reduced CIN 2/3 progression vs placebo. Similar mechanism to DIM. Adjunct only — standard screening/treatment foundational.
Phase I & II Detoxification Support
Induces both Phase I (CYP enzymes) and Phase II (sulfation, glucuronidation, glutathione conjugation) detoxification — supports clearance of estrogens, environmental toxins, drugs.
Antioxidant / Anti-Inflammatory
Modest direct antioxidant activity plus support of endogenous antioxidant systems. Anti-inflammatory effects via NF-κB modulation.
Mechanism of action
Conversion to DIM and Other Active Metabolites
I3C itself is largely converted in the acidic stomach environment to DIM (3,3'-diindolylmethane), ascorbigen, and indolo[3,2-b]carbazole (ICZ). I3C is essentially a 'pro-drug' for these active metabolites — DIM is the most studied.
CYP1A1/CYP1A2 Induction (Same as DIM)
Promotes estrogen 2-hydroxylation pathway. Same fundamental mechanism as DIM since I3C converts to DIM.
Aryl Hydrocarbon Receptor (AhR) Activation
ICZ (indolocarbazole) — an I3C metabolite — is one of the most potent natural AhR ligands. Activates extensive xenobiotic metabolism gene expression.
Anti-HPV Effects
Antiviral activity against HPV in cell culture. Mechanism for cervical dysplasia and RRP applications.
Clinical trials
Trial of I3C (400 mg/day) in healthy women for 2 months measuring urinary estrogen metabolites.
Healthy women.
Significantly increased 2-OH:16-alpha-OH estrogen metabolite ratio. Established I3C effects on estrogen metabolism.
Trial of I3C (400 mg/day) in patients with recurrent respiratory papillomatosis.
RRP patients.
Reduced recurrence rate in some patients. Generated interest in I3C as RRP adjunct. Limited subsequent confirmatory research.
About this ingredient
INDOLE-3-CARBINOL (I3C) is a GLUCOSINOLATE-DERIVED COMPOUND found in CRUCIFEROUS VEGETABLES — broccoli, cabbage, kale, cauliflower, brussels sprouts, bok choy, watercress, arugula. FORMED ENZYMATICALLY when RAW vegetables are chewed/cut: glucobrassicin (a glucosinolate) is hydrolyzed by myrosinase enzyme to I3C plus glucose and sulfate. COOKING DESTROYS MYROSINASE — but gut microbiome can perform some conversion. RELATIONSHIP TO DIM: in the acidic stomach, I3C undergoes acid-catalyzed condensation to form DIM (the more stable, more bioavailable active metabolite). I3C IS ESSENTIALLY A 'PRO-DRUG' for DIM and other indole metabolites. EVIDENCE-BASED USES (similar to DIM since I3C → DIM): (1) Estrogen metabolism modulation (Bradlow 1999); (2) PMS / hormonal symptoms; (3) Fibrocystic breasts; (4) RECURRENT RESPIRATORY PAPILLOMATOSIS (Rosen 1998) — distinct application beyond DIM evidence; (5) Cervical dysplasia adjunct (Bell 2000); (6) Phase I & II detoxification support.
CRITICAL CAUTIONS: (1) I3C VS DIM CHOICE — DIM is generally preferred for most indications because: more stable, more bioavailable, more consistent conversion than I3C; I3C conversion to DIM is variable based on gastric pH and other factors; some practitioners still prefer I3C particularly for RRP (where Rosen 1998 used I3C specifically); (2) ORAL CONTRACEPTIVES — I3C accelerates estrogen metabolism; theoretical reduction in contraceptive efficacy; consider backup; (3) PREGNANCY/LACTATION — INSUFFICIENT SAFETY DATA; AVOID; (4) HORMONE-SENSITIVE CANCERS — same complex theoretical considerations as DIM; consult oncologist; (5) WARFARIN INTERACTION — case reports of INCREASED INR with I3C; monitor closely if combining; (6) CYP1A2 INDUCTION — affects caffeine, tizanidine, theophylline, others; (7) GASTRIC ACIDITY — I3C requires acidic stomach for conversion to DIM; if on PPIs (omeprazole, pantoprazole, etc.) or with achlorhydria, conversion may be reduced; DIM supplementation more reliable in this context; (8) DOSE — 200-400 mg/day; some research uses 200 mg BID; RRP trial used 400 mg/day; (9) DIETARY CRUCIFEROUS VEGETABLES provide I3C (when raw or lightly cooked) plus other beneficial compounds; foundational approach; therapeutic supplementation when clinical indication; (10) RAW VS COOKED CRUCIFEROUS — raw provides intact myrosinase for I3C generation; lightly steamed (3-5 min) preserves some myrosinase activity; heavily cooked destroys it but releases other beneficial compounds; both have value; (11) THYROID FUNCTION — high-dose I3C from raw cruciferous (or supplements) theoretically affects thyroid (goitrogenic compounds in raw cruciferous); modest concern; relevant for those with thyroid conditions; cooking eliminates this concern; (12) The original 'cancer prevention' research on cruciferous vegetables led to I3C/DIM development — both are reasonable evidence-based options; DIM has accumulated more recent research.